ReproCELL Incorporated
Tokyo Stock Exchange 4978.T
ReproCELL Incorporated Return on Equity (ROE) for the year ending March 31, 2024: -0.38%
-
ReproCELL Incorporated Return on Equity (ROE) for the year ending March 31, 2023 was -4.03%, a 49.18% change year over year.
-
ReproCELL Incorporated Return on Equity (ROE) for the year ending March 31, 2022 was -7.93%, a 47.44% change year over year.
-
ReproCELL Incorporated Return on Equity (ROE) for the year ending March 31, 2021 was -15.09%, a 10.17% change year over year.
-
ReproCELL Incorporated Return on Equity (ROE) for the year ending March 31, 2020 was -16.80%, a -97.49% change year over year.
| Date | Return on Equity (ROE) | Return on Capital Employed (ROCE) | Interest Coverage Ratio | Debt to Equity Ratio |
|---|
Don’t Miss A Beat
| CEO | Dr. Shuji Yokoyama Ph.D. |
| IPO Date | June 26, 2013 |
| Location | Japan |
| Headquarters | MetLife Shin-Yokohama Building |
| Employees | 96 |
| Sector | Healthcare |
| Industries | |
ReproCELL Incorporated operates as a stem cell research company in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, pluripotent stem cell culture media, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder cells, and induced neurons; and 3D cell culture; and labware. The company also provides preclinical genomics, stem cell research, drug efficacy, safety, & ADME, human tissue samples, therapeutic pipeline, clinical laboratory services, clinical diagnostic services, and gmp ipsc master cell bank services. ReproCELL Incorporated was incorporated in 2003 and is based in Yokohama, Japan.
Past 5 years
USD 0.92
USD 0.17
StockViz Staff
February 10, 2025
Any question? Send us an email